Τίτλος:
Clinical study of hyperglycemia and SARS-CoV-2 infection in intensive care unit patients
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background/Aim: Reports indicate that coronaviridae may inhibit insulin secretion. In this report we aimed to describe the course of glycemia in critically ill patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Patients and Methods: We studied 36 SARS-CoV-2 patients (with no history of diabetes) in one intensive care unit (ICU). All the patients were admitted for hypoxemic respiratory failure; all but four required mechanical ventilation. The mean (±SD) age of the patients was 64.7 (9.7) years; 27 were men; the mean (±SD) duration of ICU stay was 12.9 (8.3 days). Results: Twenty of 36 patients presented with hyperglycemia; brief intravenous infusions of short-acting insulin were administered in six patients. As of May 29 2020, 11 patients had died (seven with hyperglycemia). In 17 patients the Hyperglycemia Index [HGI; defined as the area under the curve of (hyper)glycemia level time (h) divided by the total time in the ICU] was <16.21 mg/dl (0.90 mmol/l), whereas in three patients the HGI was ≥16.21 mg/dl (0.90 mol/l) and <32.25 mg/dl (1.79 mmol/l). Conclusion: In our series of ICU patients with SARS-CoV-2 infection, and no history of diabetes, a substantial number of patients had hyperglycemia, to a higher degree than would be expected by the stress of critical illness, lending credence to reports that speculated a tentative association between SARS-CoV-2 and hyperglycemia. This finding is important, since hyperglycemia can lead to further infectious complications. © 2020 International Institute of Anticancer Research. All rights reserved.
Συγγραφείς:
ILIAS, I.
JAHAJ, E.
KOKKORIS, S.
ZERVAKIS, D.
TEMPERIKIDIS, P.
MAGIRA, E.
PRATIKAKI, M.
VASSILIOU, A.G.
ROUTSI, C.
KOTANIDOU, A.
DIMOPOULOU, I.
Περιοδικό:
In vivo (Athens, Greece)
Εκδότης:
International Institute of Anticancer Research
Λέξεις-κλειδιά:
glucose; short acting insulin; insulin, adult; Article; artificial ventilation; blood glucose monitoring; clinical article; clinical trial; coronavirus disease 2019; critical illness; critically ill patient; disease course; female; glucose blood level; hospital mortality; human; hyperglycemia; hypoxemia; insulin treatment; length of stay; male; medical intensive care unit; nonhuman; respiratory failure; Severe acute respiratory syndrome coronavirus 2; stress; Betacoronavirus; complication; Coronavirus infection; diabetes mellitus; genetics; hospitalization; hyperglycemia; intensive care unit; metabolism; middle aged; pandemic; pathogenicity; pathophysiology; respiratory failure; severe acute respiratory syndrome; virology; virus pneumonia, Betacoronavirus; Blood Glucose; Coronavirus Infections; Diabetes Mellitus; Female; Hospitalization; Humans; Hyperglycemia; Insulin; Intensive Care Units; Male; Middle Aged; Pandemics; Pneumonia, Viral; Respiration, Artificial; Respiratory Insufficiency; Severe Acute Respiratory Syndrome
DOI:
10.21873/invivo.12136
